Last reviewed · How we verify
GSK1024850A (SynflorixTM)
Synflorix is a pneumococcal conjugate vaccine that stimulates immune responses against multiple serotypes of Streptococcus pneumoniae.
Synflorix is a pneumococcal conjugate vaccine that stimulates immune responses against multiple serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal otitis media and pneumonia in pediatric populations.
At a glance
| Generic name | GSK1024850A (SynflorixTM) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains polysaccharide antigens from 13 serotypes of pneumococcus conjugated to a protein carrier, which enhances immunogenicity and promotes both antibody and T-cell mediated immunity. This induces protective antibodies against the targeted pneumococcal strains, reducing the risk of invasive pneumococcal disease and related infections.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children
- Prevention of pneumococcal otitis media and pneumonia in pediatric populations
Common side effects
- Injection site erythema
- Injection site swelling
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib (PHASE3)
- Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1024850A (SynflorixTM) CI brief — competitive landscape report
- GSK1024850A (SynflorixTM) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI